Boyko OV - Search Results

1

[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].

Boyko AN, Boyko OV, Bakhtiyarova KZ, Gusev EI, Dudin VA, Zaslavsky LG, Malkova NA, Parshina YV, Poverennova IY, Siverceva SA, Totolyan NA, Shchur SG, Fedulov AS, Khabirov FA, Bolsun DD, Zinkina-Orikhan AV, Linkova YN, Chernovskaya TV. Boyko AN, et al. Among authors: boyko ov. Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(1):62-71. doi: 10.17116/jnevro202212201162. Zh Nevrol Psikhiatr Im S S Korsakova. 2022. PMID: 35175704 Clinical Trial. Russian.

2

[The results of a randomized open multicenter comparative study on the tolerability and safety of gilenya (fingolimod) in patients with remitting multiple sclerosis].

Popova EV, Boyko AN, Boyko OV. Popova EV, et al. Among authors: boyko an, boyko ov. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(2 Pt 2):45-50. doi: 10.17116/jnevro20151152245-50. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PMID: 26081336 Russian.

3

New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.

Boyko A, Kobelt G, Berg J, Boyko O, Popova E, Capsa D, Eriksson J; European Multiple Sclerosis Platform. Boyko A, et al. Mult Scler. 2017 Aug;23(2_suppl):155-165. doi: 10.1177/1352458517708668. Mult Scler. 2017. PMID: 28643590

4

Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis.

Boyko AN, Boyko OV. Boyko AN, et al. Among authors: boyko ov. Degener Neurol Neuromuscul Dis. 2018 May 3;8:35-44. doi: 10.2147/DNND.S161450. eCollection 2018. Degener Neurol Neuromuscul Dis. 2018. PMID: 30050387 Free PMC article. Review.

5

[The improvement of quality of life of patients with multiple sclerosis over 15-year period].

Boyko OV, Tatarinova MY, Popova EV, Guseva MR, Boyko AN, Gusev EI. Boyko OV, et al. Among authors: boyko an. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):23-28. doi: 10.17116/jnevro201811808223. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PMID: 30160664 Russian.

6

[Primary-progressive multiple sclerosis in Russia: a medical-sociological study involving patients and neurologists].

Vlasov YV, Churakov MV, Kurapov MA, Gromova TN, Popova EV, Boyko OV, Spirin NN, Sivertseva SA, Belskaya GN, Malkova NA, Habirov FA, Haybullin TI, Kotov SV, Greshnova IV, Ivashinenkova EI, Bakalova MA, Yampolskaya-Gosteva IA, Boyko AN. Vlasov YV, et al. Among authors: boyko an, boyko ov. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):40-46. doi: 10.17116/jnevro201811808240. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PMID: 30160667 Russian.

7

[Additional possible mechanisms of the action of ocrelizumab in multiple sclerosis on example of a case-report].

Boyko OV, Khoroshylova II, Petrov SV, Lush NY, Guseva ME, Boyko AN. Boyko OV, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):116-120. doi: 10.17116/jnevro2018118082116. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PMID: 30160679 Russian.

8

[Influence of psychopathological factors and personality traits on the results of the study of quality of life in patients with multiple sclerosis].

Malygin VL, Boyko AN, Konovalova OE, Iskandirova AS, Dumbrova EV, Boyko OV, Malygin YV. Malygin VL, et al. Among authors: boyko ov. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):42-48. doi: 10.17116/jnevro20191192242. Zh Nevrol Psikhiatr Im S S Korsakova. 2019. PMID: 31156240 Russian.

9

[Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety].

Boyko OV, Boyko AN, Yakovlev PA, Zinkina-Orikhan AV, Kotov SV, Linkova YN, Prakhova LN, Totolian NA, Shchur SG, Ivanov RA. Boyko OV, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):87-95. doi: 10.17116/jnevro201911910287. Zh Nevrol Psikhiatr Im S S Korsakova. 2019. PMID: 31934993 Clinical Trial. Russian.

10

[Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab].

Boyko OV, Choroshilova II, Petrov SV, Melnikov MV, Boyko AN. Boyko OV, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):120-127. doi: 10.17116/jnevro2019119102120. Zh Nevrol Psikhiatr Im S S Korsakova. 2019. PMID: 31934997 Russian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters